喜炎平注射液治疗慢性阻塞性肺疾病急性加重期疗效的Meta分析  

Curative effect meta-analysis of Xiyanping injection for treatment of acute exacerbation of chronic obstructive pulmonary disease

作　　者：廖音娟[1] 董李晨 左美玲[1] 

机构地区：[1]湖南省长沙市第四医院药剂科,湖南长沙410006

出　　处：《中国现代医学杂志》2016年第20期102-106,共5页China Journal of Modern Medicine

摘　　要：目的评价喜炎平注射液治疗慢性阻塞性肺疾病急性加重期的疗效。方法检索国内外公开发表的有关喜炎平注射液治疗慢性阻塞性肺疾病急性加重期的随机对照试验研究,纳入试验的质量用Jadad评分表评价,进行Meta分析。结果纳入11项研究,Meta分析结果显示,喜炎平注射液组在总有效率、白细胞计数、中性粒细胞计数、C反应蛋白、二氧化碳分压、氧分压及FEV1占预计值方面的结果指标均优于对照组。结论喜炎平注射液治疗慢性阻塞性肺疾病急性加重期具有较好的疗效,但由于现有研究质量较差,尚需设计严谨的多中心、大样本随机对照试验进一步证实。Objective To evaluate of curative effect of Xiyanping injection in treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods We searched the randomized controlled trials that Xiyanping injection in the treatment of AECOPD published at home and abroad. The quality of the inclusion researches were estimated by Jadad scale, and the data were analyzed by meta-analysis. Results A total of 11 studies were included. Comparing to control group, Xiyanping showed better therapeutic outcomes regarding to total effective rate, white blood cell count, neutrophilic granulocyte count, C reactive protein （CRP）, partial pressure of carbon dioxide, oxygen partial pressure, and FEV1/anticipated. Conclusions Xiyanping injection has better therapeutic effect on AECOPD. The results should be verified by well-designed and large-scale sample randomized control trials because of the poor quality of present research.

关 键 词：喜炎平注射液 慢性阻塞性肺疾病急性加重期 META分析 

分 类 号：R563[医药卫生—呼吸系统]